Literature DB >> 24911462

Vascular pathobiology in chronic liver disease and cirrhosis - current status and future directions.

Yasuko Iwakiri1, Vijay Shah2, Don C Rockey3.   

Abstract

Chronic liver disease is associated with remarkable alterations in the intra- and extrahepatic vasculature. Because of these changes, the fields of liver vasculature and portal hypertension have recently become closely integrated within the broader vascular biology discipline. As developments in vascular biology have evolved, a deeper understanding of vascular processes has led to a better understanding of the mechanisms of the dynamic vascular changes associated with portal hypertension and chronic liver disease. In this context, hepatic vascular cells, such as sinusoidal endothelial cells and pericyte-like hepatic stellate cells, are closely associated with one another, where they have paracrine and autocrine effects on each other and themselves. These cells play important roles in the pathogenesis of liver fibrosis/cirrhosis and portal hypertension. Further, a variety of signaling pathways have recently come to light. These include growth factor pathways involving cytokines such as transforming growth factor β, platelet derived growth factor, and others as well as a variety of vasoactive peptides and other molecules. An early and consistent feature of liver injury is the development of an increase in intra-hepatic resistance; this is associated with changes in hepatic vascular cells and their signaling pathway that cause portal hypertension. A critical concept is that this process aggregates signals to the extrahepatic circulation, causing derangement in this system's cells and signaling pathways, which ultimately leads to the collateral vessel formation and arterial vasodilation in the splanchnic and systemic circulation, which by virtue of the hydraulic derivation of Ohm's law (pressure = resistance × flow), worsens portal hypertension. This review provides a detailed review of the current status and future direction of the basic biology of portal hypertension with a focus on the physiology, pathophysiology, and signaling of cells within the liver, as well as those in the mesenteric vascular circulation. Translational implications of recent research and the future directions that it points to are also highlighted.
Copyright © 2014 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Endothelial cell; Pericyte; Pressure; Resistance; Sinusoid; Therapy

Mesh:

Year:  2014        PMID: 24911462      PMCID: PMC4346093          DOI: 10.1016/j.jhep.2014.05.047

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  129 in total

Review 1.  "Sprouting angiogenesis", a reappraisal.

Authors:  Domenico Ribatti; Enrico Crivellato
Journal:  Dev Biol       Date:  2012-09-29       Impact factor: 3.582

2.  Hepatic vascular endothelial growth factor regulates recruitment of rat liver sinusoidal endothelial cell progenitor cells.

Authors:  Lin Wang; Xiangdong Wang; Lei Wang; Jenny D Chiu; Gijs van de Ven; William A Gaarde; Laurie D Deleve
Journal:  Gastroenterology       Date:  2012-08-15       Impact factor: 22.682

3.  Complementary vascular and matrix regulatory pathways underlie the beneficial mechanism of action of sorafenib in liver fibrosis.

Authors:  Dominique Thabut; Chittaranjan Routray; Gwen Lomberk; Uday Shergill; Kevin Glaser; Robert Huebert; Leena Patel; Tetyana Masyuk; Boris Blechacz; Andrew Vercnocke; Erik Ritman; Richard Ehman; Raul Urrutia; Vijay Shah
Journal:  Hepatology       Date:  2011-06-26       Impact factor: 17.425

4.  Fibronectin induces endothelial cell migration through β1 integrin and Src-dependent phosphorylation of fibroblast growth factor receptor-1 at tyrosines 653/654 and 766.

Authors:  Li Zou; Sheng Cao; Ningling Kang; Robert C Huebert; Vijay H Shah
Journal:  J Biol Chem       Date:  2012-01-14       Impact factor: 5.157

5.  Disruption of Notch1 induces vascular remodeling, intussusceptive angiogenesis, and angiosarcomas in livers of mice.

Authors:  Michael T Dill; Sonja Rothweiler; Valentin Djonov; Ruslan Hlushchuk; Luigi Tornillo; Luigi Terracciano; Silvia Meili-Butz; Freddy Radtke; Markus H Heim; David Semela
Journal:  Gastroenterology       Date:  2012-01-12       Impact factor: 22.682

Review 6.  The scarring of the liver acini (Cirrhosis). Tridimensional and microcirculatory considerations.

Authors:  A M Rappaport; P J MacPhee; M M Fisher; M J Phillips
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1983

7.  Asymmetric dimethylarginine (ADMA) determines the improvement of hepatic endothelial dysfunction by vitamin E in cirrhotic rats.

Authors:  Ying-Ying Yang; Tzung-Yan Lee; Yi-Tsau Huang; Che-Chang Chan; Yi-Chen Yeh; Fa-Yauh Lee; Shou-Dong Lee; Han-Chieh Lin
Journal:  Liver Int       Date:  2011-10-03       Impact factor: 5.828

8.  Enhanced vasoconstrictor prostanoid production by sinusoidal endothelial cells increases portal perfusion pressure in cirrhotic rat livers.

Authors:  Jorge Gracia-Sancho; Bàrbara Laviña; Aina Rodríguez-Vilarrupla; Héctor García-Calderó; Jaime Bosch; Joan Carles García-Pagán
Journal:  J Hepatol       Date:  2007-04-05       Impact factor: 25.083

9.  Three-day tetrahydrobiopterin therapy increases in vivo hepatic NOS activity and reduces portal pressure in CCl4 cirrhotic rats.

Authors:  Vasilica Matei; Aina Rodríguez-Vilarrupla; Ramon Deulofeu; Héctor García-Calderó; Mercedes Fernández; Jaime Bosch; Joan-Carles Garcia-Pagán
Journal:  J Hepatol       Date:  2008-05-22       Impact factor: 25.083

10.  Anti-VEGF receptor-2 monoclonal antibody prevents portal-systemic collateral vessel formation in portal hypertensive mice.

Authors:  Mercedes Fernandez; Francesco Vizzutti; Juan Carlos Garcia-Pagan; Juan Rodes; Jaime Bosch
Journal:  Gastroenterology       Date:  2004-03       Impact factor: 22.682

View more
  76 in total

1.  Ascites symptom inventory-7 is a valuable tool for evaluating the effectiveness of tolvaptan in patients with cirrhotic ascites.

Authors:  Hideto Kawaratani; Kei Moriya; Tadashi Namisaki; Naotaka Shimozato; Kosuke Kaji; Hiroaki Takaya; Yukihisa Fujinaga; Yasuhiko Sawada; Shinya Sato; Soichiro Saikawa; Takuya Kubo; Takemi Akahane; Hiroshi Fukui; Hitoshi Yoshiji
Journal:  Exp Ther Med       Date:  2020-11-10       Impact factor: 2.447

2.  Band ligation versus no intervention for primary prevention of upper gastrointestinal bleeding in adults with cirrhosis and oesophageal varices.

Authors:  Sonam Vadera; Charles Wei Kit Yong; Lise Lotte Gluud; Marsha Y Morgan
Journal:  Cochrane Database Syst Rev       Date:  2019-06-20

Review 3.  Novelties in the pathophysiology and management of portal hypertension: new treatments on the horizon.

Authors:  Seong Hee Kang; Moon Young Kim; Soon Koo Baik
Journal:  Hepatol Int       Date:  2017-07-11       Impact factor: 6.047

Review 4.  Angiogenesis, Invasion, and Metastasis Characteristics of Hepatocellular Carcinoma.

Authors:  Şirin Yüksel; Cemaliye Boylu Akyerli; M Cengiz Yakıcıer
Journal:  J Gastrointest Cancer       Date:  2017-09

5.  Hepatitis C virus-induced tumor-initiating cancer stem-like cells activate stromal fibroblasts in a xenograft tumor model.

Authors:  Reina Sasaki; Pradip Devhare; Ratna B Ray; Ranjit Ray
Journal:  Hepatology       Date:  2017-10-30       Impact factor: 17.425

Review 6.  Antifibrotic therapies in the liver.

Authors:  W Z Mehal; D Schuppan
Journal:  Semin Liver Dis       Date:  2015-05-14       Impact factor: 6.115

7.  Drainage of inflammatory macromolecules from the brain to periphery targets the liver for macrophage infiltration.

Authors:  Linlin Yang; Jessica A Jiménez; Alison M Earley; Victoria Hamlin; Victoria Kwon; Cameron T Dixon; Celia E Shiau
Journal:  Elife       Date:  2020-07-31       Impact factor: 8.140

Review 8.  Renal dysfunction in cirrhosis.

Authors:  Nathalie H Urrunaga; Ayse L Mindikoglu; Don C Rockey
Journal:  Curr Opin Gastroenterol       Date:  2015-05       Impact factor: 3.287

Review 9.  Systemic hemodynamics in advanced cirrhosis: Concerns during perioperative period of liver transplantation.

Authors:  Tomohide Hori; Yasuhiro Ogura; Yasuharu Onishi; Hideya Kamei; Nobuhiko Kurata; Motoshi Kainuma; Hideo Takahashi; Shogo Suzuki; Takashi Ichikawa; Shoko Mizuno; Tadashi Aoyama; Yuki Ishida; Takahiro Hirai; Tomoko Hayashi; Kazuko Hasegawa; Hiromu Takeichi; Atsunobu Ota; Yasuhiro Kodera; Hiroyuki Sugimoto; Taku Iida; Shintaro Yagi; Kentaro Taniguchi; Shinji Uemoto
Journal:  World J Hepatol       Date:  2016-09-08

10.  Dabigatran Reduces Liver Fibrosis in Thioacetamide-Injured Rats.

Authors:  Kuei-Chuan Lee; Wei-Fan Hsu; Yun-Cheng Hsieh; Che-Chang Chan; Ying-Ying Yang; Yi-Hsiang Huang; Ming-Chih Hou; Han-Chieh Lin
Journal:  Dig Dis Sci       Date:  2018-10-04       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.